Hamiyet Donmez Altuntas

Prof. Dr. Hamiyet Donmez Altuntas

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
Stefano BonassiStefano Bonassi
Stefano Bonassi
ECErdem Coskun
Erdem Coskun
MCMarcello Ceppi
Marcello Ceppi
CLCecilia Lando
Cecilia Lando
CBClaudia Bolognesi
Claudia Bolognesi
MFMichael Fenech
Michael Fenech

29 December 2017 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZHZuhal Hamurcu
Zuhal Hamurcu
NDNesrin Delibaşı
Nesrin Delibaşı
SGSeda Geçene
Seda Geçene
EŞElif Funda Şener
Elif Funda Şener
HAHamiyet Donmez Altuntas
Hamiyet Donmez Altuntas
BOBulent ozpolat
Bulent ozpolat

1 July 1997 in Mutagenesis
Verified
Journal Article
Open access
PDF file
YÖYusuf Özkul
Yusuf Özkul
HAHamiyet Donmez Altuntas
Hamiyet Donmez Altuntas
AEAydin Erenmemisoglu
Aydin Erenmemisoglu
HDHalil Demirtas
Halil Demirtas
NINalan Imamoglu
Nalan Imamoglu
Maras Powder is a kind of smokeless tobacco widely used in lieu of cigarettes in the South-Eastern region of Turkey. In this study, we have evaluated micronuclei in buccal mucosa cells of habitual Maras Powder users. Therefore, we divided our subjects into three groups—smokeless tobacco users, smokers and non-smokers/non-users. The mean percentage of micronucleated (MN) cells was significantly higher in non-smokers/non-users (P < 0.01). The mean percentage of MN cells was 1.86 ± 0.26 in users and 1.99 ± 0.30 in smokers. There was no difference between the mean percentage of MN cells in these two groups. In conclusion, the genotoxic effect of smokeless tobacco should be considered in addition to other known hazards.

1 September 2014 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
HAHamiyet Donmez Altuntas
Hamiyet Donmez Altuntas
FSFatma Sahin
Fatma Sahin
FBFahri Bayram
Fahri Bayram
NBNazmiye Bitgen
Nazmiye Bitgen
MMMeral Mert
Meral Mert
HDHalit Diri
Halit Diri

7 February 2019 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
ZHZuhal Hamurcu
Zuhal Hamurcu
NDNesrin Delibaşı
Nesrin Delibaşı
UNUfuk Nalbantoglu
Ufuk Nalbantoglu
ESElif Funda Sener
Elif Funda Sener
NNNursultan Nurdinov
Nursultan Nurdinov
BOBulent ozpolat
Bulent ozpolat

13 February 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
AEAhmet Eken
Ahmet Eken
Mehmet Fatih YetkinMehmet Fatih Yetkin
Mehmet Fatih Yetkin
AVAlperen Vural
Alperen Vural
FOFatma Zehra Okus
Fatma Zehra Okus
SESerife Erdem
Serife Erdem
HCHalit Canatan
Halit Canatan
Sphingosine-1 phosphate receptor 1 (S1PR1) is expressed by lymphocytes and regulates their egress from secondary lymphoid organs. Innate lymphoid cell (ILC) family has been expanded with the discovery of group 1, 2 and 3 ILCs, namely ILC1, ILC2 and ILC3. ILC3 and ILC1 have remarkable similarity to CD4+ helper T cell lineage members Th17 and Th1, respectively, which are important in the pathology of multiple sclerosis (MS). Whether human ILC subsets express S1PR1 or respond to its ligands have not been studied. In this study, we used peripheral blood/cord blood and tonsil lymphocytes as a source of human ILCs. We show that human ILCs express S1PR1 mRNA and protein and migrate towards S1P receptor ligands. Comparison of peripheral blood ILC numbers between fingolimod-receiving and treatment-free MS patients revealed that, in vivo, ILCs respond to fingolimod, an S1PR1 agonist, resulting in ILC-penia in circulation. Similarly, murine ILCs responded to fingolimod by exiting blood and accumulating in the secondary lymph nodes. Importantly, ex vivo exposure of ILC3 and ILC1 to fingolimod or SEW2871, another S1PR1 antagonist, reduced production of ILC3- and ILC1- associated cytokines GM-CSF, IL-22, IL-17 and IFN-γ, respectively. Surprisingly, despite reduced number of lamina propria-resident ILC3s in the long-term fingolimod-treated mice, ILC3-associated IL-22, IL-17A, GM-CSF and antimicrobial peptides were high in the gut compared to controls, suggesting that its long term use may not compromise mucosal barrier function. To our knowledge, this is the first study to investigate the impact of fingolimod on human ILC subsets in vivo and ex vivo, and provides insight into the the impact of long term fingolimod use on ILC populations.